Apimeds Pharmaceuticals US, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Apimeds executed a 1-for-10 reverse stock split effective July 23, 2026, combining every 10 shares of old common stock into 1 new share. The company's authorized share structure remains 100M common shares and 10M preferred shares at $0.001 par. No financial operations, revenue, or business fundamentals disclosed in these exhibits.
Why this rating
Reverse split is routine capital structure adjustment, common for small-cap companies. No cash impact, no operational change. Neutral on business trajectory relative to $7.8M market cap.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.